Pfizer ' s twice-daily weight loss pill joins a long list of obesity drug flops

Pfizer' s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients…#pfizer #danuglipron #obese #novonordisk #elililly #mounjaro #eisai #fda #lorcaserin #belviq
Source: Reuters: Health - Category: Consumer Health News Source Type: news